StreetInsider.com News Articles

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 08:00:00 -0400

CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.

Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, November 5th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 08:00:00 -0400

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 08:00:00 -0400

CLEARWATER, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will present at the following investor conferences:

UBS Global Healthcare Conference – November 9-11, 2026 (Miami, FL)
Management will participate in a fireside chat at 10:15am ET and will host one-on-one meetings with investors on Monday, November 9. The fireside chat will be accessible via live webcast here.

Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services

Apyx Medical Corporation to Participate in Upcoming Investor Conferences

Wed, 21 Oct 2026 08:00:00 -0400

Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services

Form 8-K Apyx Medical Corp For: Sep 29

Tue, 29 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260929/27122740.html

Apyx Medical study links Renuvion to elastin gains in skin

Tue, 29 Sep 2026 08:02:51 -0400

Apyx Medical Corporation (NASDAQ: APYX) announced results from a prospective clinical study evaluating the effects of its Renuvion helium plasma radiofrequency technology on biological markers of skin quality. The study was published in Plastic and Reconstructive Surgery—Global Open.

The study was conducted at two U.S. sites and evaluated seven patients undergoing facelift surgery. Renuvion treatment was delivered to subdermal tissue, with untreated areas serving as internal controls. Six participants completed the Day 180 visit.

At Day 180, treated tissue showed a 30% increase in elastin fiber density and a 55% increase in elastin staining intensity compared to control tissue. Treated tissue also

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality

Tue, 29 Sep 2026 08:00:00 -0400

CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality. The study was published in Plastic and Reconstructive Surgery—Global Open 1.

The study provides new human tissue evidence indicating that Renuvion treatment may produce measurable changes beneath the surface of the skin that support improvements in skin quality

Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality

Tue, 29 Sep 2026 08:00:00 -0400

The study provides new human tissue evidence indicating that Renuvion treatment may produce measurable changes beneath the surface of the skin that support improvements in skin quality

Maxim Group Starts Apyx Medical Corp. (APYX) at Buy

Tue, 29 Sep 2026 07:42:14 -0400

Maxim Group analyst Anthony Vendetti initiates coverage on Apyx Medical Corp. (NASDAQ: APYX) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Apyx Medical Corp. click here. For more ratings news on Apyx Medical Corp. click here.

Shares of Apyx Medical Corp. closed at $2.50 yesterday.

Form 8-K Apyx Medical Corp For: Aug 06

Fri, 07 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26890794.html

Form 8-K Apyx Medical Corp For: Aug 06

Fri, 07 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26890794.html

Form 10-Q Apyx Medical Corp For: Jun 30

Thu, 06 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26885353.html

Form 10-Q Apyx Medical Corp For: Jun 30

Thu, 06 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26885353.html

Apyx Medical Corp. (APYX) Tops Q2 EPS by 2c ; Offers Guidance

Thu, 06 Aug 2026 16:10:45 -0400

Apyx Medical Corp. (NASDAQ: APYX) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $13.32 million.

GUIDANCE:

Apyx Medical Corp. sees FY2026 revenue of $59-60 million, versus the consensus of $59.55 million.

For earnings history and earnings-related data on Apyx Medical Corp. (APYX) click here.

Apyx Medical Corp. (APYX) Tops Q2 EPS by 2c ; Offers Guidance

Thu, 06 Aug 2026 16:10:45 -0400

GUIDANCE:

Apyx Medical Corp. sees FY2026 revenue of $59-60 million, versus the consensus of $59.55 million.

For earnings history and earnings-related data on Apyx Medical Corp. (APYX) click here.

Form 8-K Apyx Medical Corp For: Aug 06

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883901.html

Form 8-K Apyx Medical Corp For: Aug 06

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883901.html

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment
Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026
Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million
Management to host a conference call today at 4:30 p.m. ET